PDCD1 and neoplasm: In the CheckMate 025 trial, high FCER1G expression was suggestive of poor prognosis in patients treated with an anti-PD-1 agent which is a monoclonal antibody that acts by blocking inhibitory transmembrane protein expressed on T cells to in turn stimulate the anti-tumor immune response.